Pancreatic Neuroendocrine Tumor Biomarker Expression and Survival Outcomes

A retrospective analysis of 58 surgically resected primary pancreatic neuroendocrine tumor (PanNET) samples. The dataset includes immunohistochemical evaluations of ATRX, DAXX, ARX, PDX1, and somatostatin receptors (SSTR2a/5). It was authored by Oana A. Ciobanu and last updated on May 11, 2026.

Use Cases

• Assess associations between biomarker expression and clinicopathological parameters based on immunohistochemical scores.
• Explore relationships between biomarker status and recurrence-free survival (RFS), cancer-specific survival (CSS), and overall survival (OS) based on Kaplan–Meier analysis.
• Investigate the predictive value of tumor size for ATRX/DAXX loss based on ROC curve analysis in tumors ≥2 cm.
• Compare biomarker prevalence between functional and nonfunctional PanNET groups based on the study's cohort analysis.

Strengths

• Includes data from 58 surgically resected primary tumor samples.
• Provides quantitative expression scores and results from receiver operating characteristic (ROC) curve analysis.
• Reports specific survival outcomes, such as a median OS of 73 months for SSTR5-positive tumors.

Limitations

• Row count is unknown, which may limit suitability assessment.
• Column-level documentation is absent; field semantics must be inferred after download.
• The dataset is very small at 24.9 KB, indicating limited scope.

Provenance

Source

figshare

Collection Method

Retrospective analysis of surgically resected tumor samples with immunohistochemical evaluation.

Freshness

Last updated 2026-05-11 04:23:45; freshness should be verified.